Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.

doi:10.1158/2159-8290.CD-23-0456

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.

Cancer discovery - 12 Jan 2024

Wong Derek, Luo Ping, Oldfield Leslie E, Gong Haifan, Brunga Ledia, Rabinowicz Ron, Subasri Vallijah, Chan Clarissa, Downs Tiana, Farncombe Kirsten M, Luu Beatrice, Norman Maia, Sobotka Julia A, Uju Precious, Eagles Jenna, Pedersen Stephanie, Wellum Johanna, Danesh Arnavaz, Prokopec Stephenie D, Stutheit-Zhao Eric Y, Znassi Nadia, Heisler Lawrence E, Jovelin Richard, Lam Bernard, Lujan Toro Beatriz E, Marsh Kayla, Sundaravadanam Yogi, Torti Dax, Man Carina, Goldenberg Anna, Xu Wei, Veit-Haibach Patrick, Doria Andrea S, Malkin David, Kim Raymond H, Pugh Trevor J

Abstract excerpt

People with Li-Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to Early Detection of Cancer

Share to Genes, p53

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Li-Fraumeni Syndrome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 37874259
DOI: 10.1158/2159-8290.CD-23-0456
PMCID: PMC10784744

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.PMID 37874259Read ↗

Integrated analysis of cell-free DNA for the early detection of cancer in people with Li-Fraumeni SyndromeSemantic proximity Read ↗

Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detectionSemantic proximity Read ↗

Cell-free DNA approaches for cancer early detection and interception.Semantic proximity Read ↗

Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.Semantic proximity Read ↗

Early Cancer Detection in Hereditary Breast and Ovarian Cancer Syndrome with Cell-Free DNASemantic proximity Read ↗

Is It Time to Incorporate Liquid Biopsy into High-Risk Cancer Surveillance Protocols in Li–Fraumeni Syndrome?Semantic proximity Read ↗

Update on Cancer Screening Recommendations for Individuals with Li–Fraumeni SyndromeSemantic proximity Read ↗

New Paradigms in the Clinical Management of Li-Fraumeni Syndrome.Semantic proximity Read ↗

Inherited TP53 Mutations and the Li-Fraumeni Syndrome.Semantic proximity Read ↗

Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome.Semantic proximity Read ↗

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?Semantic proximity Read ↗

Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.